These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8302545)

  • 1. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy.
    Hill JC
    Ophthalmology; 1994 Jan; 101(1):128-33. PubMed ID: 8302545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic cyclosporine in high-risk keratoplasty: long-term results.
    Hill JC
    Eye (Lond); 1995; 9 ( Pt 4)():422-8. PubMed ID: 7498559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix.
    Mahlberg K; Uusitalo RJ; Oksala O
    Ocul Immunol Inflamm; 1997 Jun; 5(2):101-10. PubMed ID: 9234374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine.
    Yamazoe K; Yamazoe K; Yamaguchi T; Omoto M; Shimazaki J
    Cornea; 2014 Nov; 33(11):1157-63. PubMed ID: 25255133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].
    Bailly N; Dunewa I; Schlattmann P; Rieck PW
    Ophthalmologe; 2008 May; 105(5):457-62. PubMed ID: 18299847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.
    Poon AC; Forbes JE; Dart JK; Subramaniam S; Bunce C; Madison P; Ficker LA; Tuft SJ; Gartry DS; Buckley RJ
    Br J Ophthalmol; 2001 Dec; 85(12):1464-9. PubMed ID: 11734522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of corneal allograft rejection by systemic cyclosporine-A in heavily vascularized rabbit corneas following alkali burns.
    Rehany U; Waisman M
    Cornea; 1994 Sep; 13(5):447-53. PubMed ID: 7995070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical cyclosporine in pediatric keratoplasty.
    Cosar CB; Laibson PR; Cohen EJ; Rapuano CJ
    Eye Contact Lens; 2003 Apr; 29(2):103-7. PubMed ID: 12695714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment.
    Zhang T; Li Z; Liu T; Li S; Gao H; Wei C; Shi W
    PLoS One; 2018; 13(5):e0196571. PubMed ID: 29734357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study.
    Shi W; Chen M; Xie L; Liu M; Gao H; Wang T; Wu X; Zhao J
    Ophthalmology; 2013 Apr; 120(4):695-702. PubMed ID: 23246118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression.
    Chow SP; Cook SD; Tole DM
    Cornea; 2015 Nov; 34(11):1395-9. PubMed ID: 26382894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats.
    Bourges JL; Lallemand F; Agla E; Besseghir K; Dumont JM; BenEzra D; Gurny R; Behar-Cohen F
    Mol Vis; 2006 Dec; 12():1461-6. PubMed ID: 17167400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term graft survival after penetrating keratoplasty.
    Thompson RW; Price MO; Bowers PJ; Price FW
    Ophthalmology; 2003 Jul; 110(7):1396-402. PubMed ID: 12867398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.
    Lee JJ; Kim MK; Wee WR
    Graefes Arch Clin Exp Ophthalmol; 2015 Jul; 253(7):1111-9. PubMed ID: 25896110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat.
    Juberías JR; Calonge M; Gómez S; López MI; Calvo P; Herreras JM; Alonso MJ
    Curr Eye Res; 1998 Jan; 17(1):39-46. PubMed ID: 9472469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed lymphocyte culture responses in rabbits undergoing corneal grafting and topical cyclosporine treatment.
    Maske R; Hill JC; Horak S
    Cornea; 1994 Jul; 13(4):324-30. PubMed ID: 7924332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.
    Birnbaum F; Böhringer D; Sokolovska Y; Sundmacher R; Reinhard T
    Transplantation; 2005 Apr; 79(8):964-8. PubMed ID: 15849551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of corneal graft survival in infants and children with peters anomaly.
    Yang LL; Lambert SR; Lynn MJ; Stulting RD
    Ophthalmology; 1999 Apr; 106(4):833-48. PubMed ID: 10201611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Penetrating keratoplasty in high-risk children: prevention of graft rejection].
    Pleskova AV; Khvatova AV
    Vestn Oftalmol; 2014; 130(3):17-20. PubMed ID: 25098116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
    Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.